Viewing nowCombinationNew Vica Tablet 5/20mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 201601780 · Approved 2016.04.04 · Insurance code 669906670
Treatment of essential hypertension
Amlodipine or Olmesartan Medoxomil is used when blood pressure is not adequately controlled in patients with essential hypertension. These medications help to maintain stable blood pressure by dilating blood vessels or lowering blood pressure. Regular use can effectively reduce the cardiovascular risks associated with hypertension and protect health. Therefore, it is used for the management of essential hypertension.
Take 1 tablet once daily with water, with or without food. It is recommended that the medication be taken at the same time each day (e.g., in the morning), if possible. It is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted before starting this medication; however, switching directly to this medication may be considered if blood pressure is not adequately controlled with monotherapy using either component. The maximum dose of this medication is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using amlodipine 5 mg or olmesartan medoxomil 20 mg. - 10/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using olmesartan medoxomil 20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering this medication to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medication should not be administered to patients with severe hepatic impairment. (See section 2, “Patients who should not receive this medication,” under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
∘Pediatric patients: Safety and efficacy have not been established in pediatric patients under 18 years of age.
This drug can cause serious harm or death to the fetus and neonate if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to the active ingredient or similar components, those who are pregnant or breastfeeding, patients with severe liver impairment, severe aortic stenosis, biliary obstruction, patients on renal dialysis, patients in shock, specific diabetic patients, and patients with moderate or severe renal impairment should not take this medication. When administering this drug to patients with depleted fluids or electrolytes, signs of low blood pressure may occur, so careful monitoring of their condition is necessary, and appropriate measures should be taken if low blood pressure occurs. Since this medication can lower blood pressure by dilating blood vessels, it should be used with caution in patients with severe aortic stenosis, obstructive coronary artery disease, and congestive heart failure. In patients with impaired kidney function, regular monitoring of renal function is required since this medication can affect kidney function. This drug is metabolized in the liver, so it should be used cautiously in patients with severe liver impairment, and dosage adjustments may be necessary. During the course of taking this drug, side effects such as dizziness, headache, hypotension, edema, indigestion, rash, etc., may occur, and patients should consult medical personnel if any abnormal symptoms appear. Particularly, during treatment with this drug, potassium levels in the blood may increase, so when combined with potassium-sparing diuretics or potassium supplements, it is advisable to frequently check potassium levels in the blood. Taking this drug with grapefruit juice may enhance its blood pressure-lowering effects; therefore, it is advisable to avoid grapefruit juice consumption. This drug should not be used during pregnancy, and if planning to conceive, it is recommended to switch to a safer alternative treatment. Breastfeeding women should either stop breastfeeding or discontinue this medication because it can be passed into breast milk. The safety and efficacy of this medication have not been established for children under 18 years of age, and it is not recommended for use in this population. In elderly patients, dosage should be adjusted carefully considering impaired liver, kidney, or heart function and accompanying diseases, and it is safer to start treatment at lower doses. In case of overdose, symptoms such as hypotension, increased heart rate, and peripheral vessel dilation may occur, and immediate medical attention should be sought for appropriate treatment. This medication should be stored in a closed container away from moisture, heat, and direct sunlight, and should be kept out of reach of children; transferring to another container should be avoided.
Not everyone experiences these, and they can vary from person to person.
This drug is sensitive to air and moisture, so it should be stored in a sealed container. It is recommended to keep it at room temperature, between 1 and 30 degrees Celsius. This will help maintain the efficacy of the medication for a longer time.
White round film-coated tablet
30 tablets/box [10 tablets/Alu-Alu*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.